High pKDR immunohistochemical expression is an unfavourable prognostic biomarker in patients with advanced colorectal cancer treated with chemotherapy plus bevacizumab

Garde-Noguera J.; Gil-Raga M.; Evgenyeva E.; Garcia J. A.; Llombart-Cussac A.; Camps-Herrero C.

首页> 外文期刊>Clinical & translational oncology : >High pKDR immunohistochemical expression is an unfavourable prognostic biomarker in patients with advanced colorectal cancer treated with chemotherapy plus bevacizumab

【24h】

High pKDR immunohistochemical expression is an unfavourable prognostic biomarker in patients with advanced colorectal cancer treated with chemotherapy plus bevacizumab

机译：高pKDR免疫组化表达是化疗加贝伐珠单抗治疗的晚期大肠癌患者不良的预后生物标志物

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

To analyse the prognostic role of the immunohistochemical expression of pKDR in patients with advanced colorectal cancer treated with oxaliplatin and fluoropyrimidines combination chemotherapy with or without bevacizumab.

机译：分析pKDR免疫组织化学表达在奥沙利铂和氟嘧啶联合化疗联合或不联合贝伐单抗治疗的晚期大肠癌患者中的预后作用。

著录项

来源
《Clinical & translational oncology :》 |2016年第4期|共8页
作者
Garde-Noguera J.; Gil-Raga M.; Evgenyeva E.; Garcia J. A.; Llombart-Cussac A.; Camps-Herrero C.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词
Colorectal cancer; Bevacizumab; Biomarkers; pKDR;

机译：大肠癌;贝伐单抗;生物标志物;pKDR;
入库时间 2022-08-18 09:39:09

相似文献

外文文献
中文文献
专利

1. High pKDR immunohistochemical expression is an unfavourable prognostic biomarker in patients with advanced colorectal cancer treated with chemotherapy plus bevacizumab [J] . Garde-Noguera J., Gil-Raga M., Evgenyeva E., Clinical & translational oncology : . 2016,第4期

机译：高pKDR免疫组化表达是化疗加贝伐珠单抗治疗的晚期大肠癌患者不良的预后生物标志物
2. The predictive and prognostic value of circulating endothelial cells in advanced colorectal cancer patients receiving first-line chemotherapy and bevacizumab. [J] . Simkens LH, Tol J, Terstappen LW, Annals of oncology: official journal of the European Society for Medical Oncology . 2010,第12期

机译：循环内皮细胞在接受一线化疗和贝伐单抗的晚期大肠癌患者中的预测和预后价值。
3. The predictive and prognostic value of circulating endothelial cells in advanced colorectal cancer patients receiving first-linen chemotherapy and bevacizumab [J] . I. D. Nagtegaal Annals of Oncology . 2010,第12期

机译：循环内皮细胞在接受一线化疗和贝伐单抗治疗的晚期大肠癌患者中的预测和预后价值
4. Correlation between development of hypertension and efficacy in metastatic colorectal cancer patients treated with bevacizumab [C] . Horinouchi Y., Sakurada T., Nakamura T., European Association for Clinical Pharmacology and Therapeutics . 2011

机译：北伐单抗治疗转移性结直肠癌患者高血压与疗效的相关性
5. Prognostic Biomarkers for Diffuse Large B Cell Lymphoma Patient Survival after Treatment with Chemotherapy: A Retrospective Analysis of 88 Cases [D] . Bushra, Hamama tul. 2019

机译：弥漫性大B细胞淋巴瘤化疗后患者生存的预后生物标志物：88例回顾性分析
6. Prognostic significance of AMPK activation in advanced stage colorectal cancer treated with chemotherapy plus bevacizumab [O] . E Zulato, F Bergamo, A De Paoli, 2014

机译：化疗加贝伐单抗治疗晚期结直肠癌中AMPK激活的预后意义
7. The dynamics of the serum concentration of CEA, CA15-3 and CA19-9 and survival in patients treated for advanced breast and colorectal cancer. The determination of the prognostic correlates of changes in tumour markers CEA, CA15-3 and CA19-9 during chemotherapy treatment for advanced breast and colorectal cancer. [O] . Barker Laura Caroline 2010

机译：晚期乳腺癌和结直肠癌患者血清CEA，CA15-3和CA19-9的浓度动态及生存率。确定晚期乳腺癌和大肠癌化疗期间肿瘤标志物CEA，CA15-3和CA19-9变化的预后相关性。

High pKDR immunohistochemical expression is an unfavourable prognostic biomarker in patients with advanced colorectal cancer treated with chemotherapy plus bevacizumab

摘要

著录项

相似文献

相关主题

期刊订阅